{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:54:53Z","timestamp":1790664893255,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The optimal duration of hypomethylating agent (HMA) therapy combined with venetoclax (Ven) in newly diagnosed acute myeloid leukemia (ND\u2010AML) remains uncertain. Standard of care (SOC) uses 5\u2010day decitabine (Dec\u20105) or 7\u2010day azacitidine (Aza\u20107), while extended HMA regimens (e.g.,\u00a010\u2010day decitabine [Dec\u201010] during cycle 1) have also been explored, although direct comparative data between these approaches are limited. We conducted a large retrospective analysis of 335 patients with ND\u2010AML treated at five US centers with Dec\u201010\/Ven (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0102) or SOC HMA\/Ven (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0233). Baseline characteristics were largely balanced, though the Dec\u201010 group had more treated secondary AML, and the SOC group had more intermediate risk by ELN\u20102024. Dec\u201010\/Ven exhibited significantly higher composite complete remission rates (CRc) (82% vs. 70%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.029), but similar measurable residual disease (MRD) negativity rates (27% vs. 25%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.6) at best response. Median overall survival (OS) was significantly longer for Dec\u201010\/Ven, 22.2 versus 9.1\u00a0months for SOC (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001). Transplantation was more frequent following Dec\u201010\/Ven (25% vs. 6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001). The 30\u2010day and 60\u2010day mortality rates were similar (7% vs. 11%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.4; 13% vs. 23%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.1). On multivariable analysis, the Dec\u201010 regimen, de novo AML, non\u2010complex karyotype, and IDH2 mutation were associated with a significantly lower risk of death. Our findings suggest that Dec\u201010\/Ven may lead to improved transplant rates and survival, providing valuable real\u2010world support for this intensified approach in appropriate patients. Prospective randomized evaluation is warranted.\n                  <\/jats:p>","DOI":"10.1002\/hon.70198","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:44:16Z","timestamp":1778939056000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9327-194X","authenticated-orcid":false,"given":"Georgio","family":"Medawar","sequence":"first","affiliation":[{"name":"Department of Hematology\u2010Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Sebastien","family":"Anoma","sequence":"additional","affiliation":[{"name":"Department of Public Health, Biostatistics Shared Resources Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-4106","authenticated-orcid":false,"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Public Health, Biostatistics Shared Resources Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Tharakan","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahniel L.","family":"Sastow","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8704-3174","authenticated-orcid":false,"given":"Vincent","family":"Lok","sequence":"additional","affiliation":[{"name":"Department of Medicine University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Bin","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Family &amp; Community Medicine University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kehoe","sequence":"additional","affiliation":[{"name":"Department of Medicine University of South Florida Morsani College of Medicine  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidambaram","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology University of Connecticut  Farmington Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Guetta\u2010Weiss","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies and Cellular Therapy Duke University Medical Center  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Meleveedu","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology University of Connecticut  Farmington Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematologic Malignancies and Cellular Therapy Duke University Medical Center  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Swoboda","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Tampa General Hospital Cancer Institute  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[{"name":"Department of Hematology\u2010Oncology Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27434"},{"key":"e_1_2_9_3_1","unstructured":"M.Stahl R. M.Stone.Acute Myeloid Leukemia: 2025 Update on Diagnosis Stratification and Management. (2025) 1\u201332."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184618"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010021\u201000784\u2010y"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283437"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201019\u20101900"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201003\u20100687"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.762093"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(20)30210\u20106"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.6549"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30024\u20109"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(18)30182\u20100"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001270\u20104"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27180"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.18686"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001416\u20104"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010170867"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027217"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010181347"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20106"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:56:25Z","timestamp":1780307785000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/hon.70198"],"URL":"https:\/\/doi.org\/10.1002\/hon.70198","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70198"}}